SARS-CoV-2感染后肺部αvβ6靶向分子PET/CT成像
本文报道一例SARS-CoV-2感染急性期后2个月的患者,使用整合素αvβ6结合肽(18F-αvβ6-BP)进行首次人体PET/CT成像。正常肺实质摄取极低,而CT显示磨玻璃影区域摄取增高。提示18F-αvβ6-BP PET/CT有望无创识别并监测肺损伤的存在与进展。
要点
- αvβ6在健康成人上皮低表达或不可测,在损伤组织(包括纤维化肺)中上调。
- 首例人体18F-αvβ6-BP PET/CT显示正常肺摄取低,CT磨玻璃影区摄取增高。
- 该技术有望无创识别并监测SARS-CoV-2感染后肺损伤的持续与进展。
核心结论
- 18F-αvβ6-BP PET/CT是识别肺损伤存在并可能监测其持续与进展的有前景的无创方法。
研究设计与样本
- 个案报道:一例SARS-CoV-2感染急性期后2个月的患者接受首次人体18F-αvβ6-BP PET/CT成像。
主要发现
- 正常肺实质中18F-αvβ6-BP摄取极低,而与CT上磨玻璃影对应的区域摄取增高。
关键数值与推荐
- αvβ6为上皮特异性细胞表面受体,在健康成人上皮低表达或不可测,在包括纤维化肺在内的特定损伤组织中上调。
临床怎么用
- 对于SARS-CoV-2感染后疑似肺损伤持续的患者,可考虑18F-αvβ6-BP PET/CT无创评估肺损伤存在及可能监测其持续与进展。
局限性
- 仅为单例病例报道,尚需更多研究验证其诊断效能与临床价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The true impact and long-term damage to organs such as the lungs after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remain to be determined. Noninvasive molecularly targeted imaging may play a critical role in aiding visualization and understanding of the systemic damage. We have identified αvβ6 as a molecular target; an epithelium-specific cell surface receptor that is low or undetectable in healthy adult epithelium but upregulated in select injured tissues, including fibrotic lung. Herein we report the first human PET/CT images using the integrin αvβ6-binding peptide (18F-αvβ6-BP) in a patient 2 mo after the acute phase of infection. Minimal uptake of 18F-αvβ6-BP was noted in normal lung parenchyma, with uptake being elevated in areas corresponding to opacities on CT. This case suggests that 18F-αvβ6-BP PET/CT is a promising noninvasive approach to identify the presence and potentially monitor the persistence and progression of lung damage.
引用
- Foster CC, Davis RA, Hausner SH, et al. αvβ6-Targeted Molecular PET/CT Imaging of the Lungs After SARS-CoV-2 Infection. J Nucl Med. 2020. PMID: 32948681. doi:10.2967/jnumed.120.255364
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。